Allosteric modulation of a chemogenetically modified G protein-coupled receptor

Alaa Abdul Ridha, Jonathan Robert David Lane, Patrick Sexton, Meritxell Canals, Arthur Christopoulos

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Designer receptors exclusively activated by designer drugs (DREADDs) are chemogenetically modified muscarinic acetylcholine receptors (mAChRs) that have minimal responsiveness to acetylcholine (ACh) but are potently and efficaciously activated by an otherwise inert synthetic ligand, clozapine-N-oxide (CNO). DREADDs have been used as tools for selectively modulating signal transduction pathways in vitro and in vivo. Recent comprehensive studies have validated how the pharmacology of a CNO-bound DREADD mirrors that of an ACh-bound wild-type (WT) mAChR. However, nothing is known about whether this equivalence extends to the allosteric modulation of DREADDs by small molecules. To address this, we investigated the actions at an M(1) DREADD of benzyl quinolone carboxylic acid (BQCA), a positive allosteric modulator of ACh binding and function that is known to behave according to a simple two-state mechanism at the WT receptor. We found that allosteric modulation of the CNO-bound DREADD receptor is not equivalent to the corresponding modulation of the ACh-bound WT receptor. We also found that BQCA engenders stimulus bias at the M(1) DREADD, having differential types of cooperativity depending on the signaling pathway. Furthermore, the modulation of ACh itself by BQCA at the DREADD is not compatible with the two-state model that we previously applied to the M(1) WT receptor.
Original languageEnglish
Pages (from-to)521 - 530
Number of pages10
JournalMolecular Pharmacology
Volume83
Issue number2
DOIs
Publication statusPublished - 2013

Cite this

Abdul Ridha, Alaa ; Lane, Jonathan Robert David ; Sexton, Patrick ; Canals, Meritxell ; Christopoulos, Arthur. / Allosteric modulation of a chemogenetically modified G protein-coupled receptor. In: Molecular Pharmacology. 2013 ; Vol. 83, No. 2. pp. 521 - 530.
@article{ec8999aecd384d2f9e5abc094419cd3e,
title = "Allosteric modulation of a chemogenetically modified G protein-coupled receptor",
abstract = "Designer receptors exclusively activated by designer drugs (DREADDs) are chemogenetically modified muscarinic acetylcholine receptors (mAChRs) that have minimal responsiveness to acetylcholine (ACh) but are potently and efficaciously activated by an otherwise inert synthetic ligand, clozapine-N-oxide (CNO). DREADDs have been used as tools for selectively modulating signal transduction pathways in vitro and in vivo. Recent comprehensive studies have validated how the pharmacology of a CNO-bound DREADD mirrors that of an ACh-bound wild-type (WT) mAChR. However, nothing is known about whether this equivalence extends to the allosteric modulation of DREADDs by small molecules. To address this, we investigated the actions at an M(1) DREADD of benzyl quinolone carboxylic acid (BQCA), a positive allosteric modulator of ACh binding and function that is known to behave according to a simple two-state mechanism at the WT receptor. We found that allosteric modulation of the CNO-bound DREADD receptor is not equivalent to the corresponding modulation of the ACh-bound WT receptor. We also found that BQCA engenders stimulus bias at the M(1) DREADD, having differential types of cooperativity depending on the signaling pathway. Furthermore, the modulation of ACh itself by BQCA at the DREADD is not compatible with the two-state model that we previously applied to the M(1) WT receptor.",
author = "{Abdul Ridha}, Alaa and Lane, {Jonathan Robert David} and Patrick Sexton and Meritxell Canals and Arthur Christopoulos",
year = "2013",
doi = "10.1124/mol.112.083006",
language = "English",
volume = "83",
pages = "521 -- 530",
journal = "Molecular Pharmacology",
issn = "1521-0111",
publisher = "ACS Books",
number = "2",

}

Allosteric modulation of a chemogenetically modified G protein-coupled receptor. / Abdul Ridha, Alaa; Lane, Jonathan Robert David; Sexton, Patrick; Canals, Meritxell; Christopoulos, Arthur.

In: Molecular Pharmacology, Vol. 83, No. 2, 2013, p. 521 - 530.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Allosteric modulation of a chemogenetically modified G protein-coupled receptor

AU - Abdul Ridha, Alaa

AU - Lane, Jonathan Robert David

AU - Sexton, Patrick

AU - Canals, Meritxell

AU - Christopoulos, Arthur

PY - 2013

Y1 - 2013

N2 - Designer receptors exclusively activated by designer drugs (DREADDs) are chemogenetically modified muscarinic acetylcholine receptors (mAChRs) that have minimal responsiveness to acetylcholine (ACh) but are potently and efficaciously activated by an otherwise inert synthetic ligand, clozapine-N-oxide (CNO). DREADDs have been used as tools for selectively modulating signal transduction pathways in vitro and in vivo. Recent comprehensive studies have validated how the pharmacology of a CNO-bound DREADD mirrors that of an ACh-bound wild-type (WT) mAChR. However, nothing is known about whether this equivalence extends to the allosteric modulation of DREADDs by small molecules. To address this, we investigated the actions at an M(1) DREADD of benzyl quinolone carboxylic acid (BQCA), a positive allosteric modulator of ACh binding and function that is known to behave according to a simple two-state mechanism at the WT receptor. We found that allosteric modulation of the CNO-bound DREADD receptor is not equivalent to the corresponding modulation of the ACh-bound WT receptor. We also found that BQCA engenders stimulus bias at the M(1) DREADD, having differential types of cooperativity depending on the signaling pathway. Furthermore, the modulation of ACh itself by BQCA at the DREADD is not compatible with the two-state model that we previously applied to the M(1) WT receptor.

AB - Designer receptors exclusively activated by designer drugs (DREADDs) are chemogenetically modified muscarinic acetylcholine receptors (mAChRs) that have minimal responsiveness to acetylcholine (ACh) but are potently and efficaciously activated by an otherwise inert synthetic ligand, clozapine-N-oxide (CNO). DREADDs have been used as tools for selectively modulating signal transduction pathways in vitro and in vivo. Recent comprehensive studies have validated how the pharmacology of a CNO-bound DREADD mirrors that of an ACh-bound wild-type (WT) mAChR. However, nothing is known about whether this equivalence extends to the allosteric modulation of DREADDs by small molecules. To address this, we investigated the actions at an M(1) DREADD of benzyl quinolone carboxylic acid (BQCA), a positive allosteric modulator of ACh binding and function that is known to behave according to a simple two-state mechanism at the WT receptor. We found that allosteric modulation of the CNO-bound DREADD receptor is not equivalent to the corresponding modulation of the ACh-bound WT receptor. We also found that BQCA engenders stimulus bias at the M(1) DREADD, having differential types of cooperativity depending on the signaling pathway. Furthermore, the modulation of ACh itself by BQCA at the DREADD is not compatible with the two-state model that we previously applied to the M(1) WT receptor.

UR - http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=23197649

U2 - 10.1124/mol.112.083006

DO - 10.1124/mol.112.083006

M3 - Article

VL - 83

SP - 521

EP - 530

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 1521-0111

IS - 2

ER -